Revance to Join June 2024 Investor Conferences

Revance Therapeutics, Inc. (NASDAQ: RVNC), based in Nashville, Tennessee, has announced its participation in two significant investor conferences. The company will be represented by its senior executives, who will discuss Revance's latest developments and future plans.

At the William Blair 44th Annual Growth Stock Conference, Revance's Chief Financial Officer, Tobin Schilke, will present on Tuesday, June 4, 2024, at 11:20 am CT in Chicago, Illinois. The focus of his presentation will be on the company's recent financial performance and growth strategies.

Following this, President and Chief Executive Officer Mark J. Foley will present at the Goldman Sachs 45th Annual Global Healthcare Conference. This event is scheduled for Tuesday, June 11, 2024, at 8:00 am ET in Miami, Florida. Foley’s presentation is expected to delve into the company's advancements in healthcare innovations and future market opportunities.

Both presentations will be available as live audio webcasts accessible through the Investor Relations section of Revance’s website. These webcasts will remain accessible for approximately 90 days after the live events, allowing interested parties ample time to engage with the content.

Revance Therapeutics is a forward-thinking biotechnology company that aims to redefine healthcare standards with its innovative aesthetic and therapeutic products. Their U.S. portfolio features DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers. In addition, the company is working in partnership with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection. They have also collaborated with Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.

The company operates from its global headquarters and experience center in Nashville, Tennessee. Revance is committed to enhancing patient outcomes and physician experiences through its cutting-edge products and treatments.

Revance has established itself as a leader in the biotech industry with its registered trademarks including "Revance," the Revance logo, and DAXXIFY. Trademarks such as Resilient Hyaluronic Acid® and RHA® are owned by TEOXANE SA.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!